Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.

Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Immunotherapy*/methods ; Neoplasms*/therapy ; Nanomedicine*/methods ; Phototherapy*/methods; Humans ; Combined Modality Therapy ; Animals ; Drug Delivery Systems/methods ; Nanoparticle Drug Delivery System/chemistry

In recent decades, cancer has posed a challenging obstacle that humans strive to overcome. While phototherapy and immunotherapy are two emerging therapies compared to traditional methods, they each have their advantages and limitations. These limitations include easy metastasis and recurrence, low response rates, and strong side effects. To address these issues, researchers have increasingly focused on combining these two therapies by utilizing a nano-drug delivery system due to its superior targeting effect and high drug loading rate, yielding remarkable results. The combination therapy demonstrates enhanced response efficiency and effectiveness, leading to a preparation that is highly targeted, responsive, and with low recurrence rates. This paper reviews several main mechanisms of anti-tumor effects observed in combination therapy based on the nano-drug delivery system over the last five years. Furthermore, the challenges and future prospects of this combination therapy are also discussed.
(© 2024. The Author(s).)

Discov Med. 2019 Jan;27(146):45-55. (PMID: 30721651)
Nat Rev Cancer. 2003 Oct;3(10):721-32. (PMID: 13130303)
Biomaterials. 2020 Feb;230:119629. (PMID: 31767446)
J Control Release. 2011 Dec 20;156(3):276-80. (PMID: 21888934)
Cancers (Basel). 2020 Oct 01;12(10):. (PMID: 33019627)
Immunotherapy. 2011 Oct;3(10):1143-66. (PMID: 21995569)
Acta Pharm Sin B. 2022 Nov;12(11):4204-4223. (PMID: 36386474)
Front Immunol. 2022 Apr 13;13:876339. (PMID: 35493513)
Nano Lett. 2013;13(12):6098-105. (PMID: 24224474)
J Antimicrob Chemother. 2013 May;68(5):977-85. (PMID: 23292347)
Small. 2021 Oct;17(43):e2102624. (PMID: 34378338)
Adv Sci (Weinh). 2021 Jan 05;8(3):2002504. (PMID: 33552860)
J Photochem Photobiol B. 1990 Jun;6(1-2):183-7. (PMID: 2146378)
Int J Cancer. 2020 Feb 15;146(4):895-905. (PMID: 30734283)
Cell. 2016 Oct 20;167(3):829-842.e13. (PMID: 27745970)
ACS Nano. 2021 Sep 28;15(9):15166-15179. (PMID: 34469109)
Lasers Surg Med. 1992;12(3):318-24. (PMID: 1387186)
Cell Metab. 2016 Jan 12;23(1):27-47. (PMID: 26771115)
J Nanobiotechnology. 2021 Sep 30;19(1):297. (PMID: 34593005)
Front Immunol. 2020 Jul 30;11:1680. (PMID: 32849585)
Nanomedicine. 2019 Jun;18:44-53. (PMID: 30844573)
Eur J Cancer. 2006 Apr;42(6):717-27. (PMID: 16520032)
Small. 2022 Feb;18(6):e2103868. (PMID: 34729913)
Nat Nanotechnol. 2021 Dec;16(12):1424-1434. (PMID: 34697491)
Asian J Pharm Sci. 2021 Nov;16(6):738-761. (PMID: 35027951)
Biomaterials. 2021 Jun;273:120788. (PMID: 33933912)
Biomaterials. 2022 Dec;291:121902. (PMID: 36371945)
Biomaterials. 2021 Sep;276:121018. (PMID: 34284200)
Biomaterials. 2021 Oct;277:121110. (PMID: 34482088)
Front Immunol. 2021 Nov 26;12:783236. (PMID: 34899747)
Theranostics. 2018 Mar 8;8(8):2229-2241. (PMID: 29721075)
Front Immunol. 2018 Mar 01;9:414. (PMID: 29545811)
Nat Rev Immunol. 2005 Aug;5(8):641-54. (PMID: 16056256)
Nat Rev Drug Discov. 2019 Feb;18(2):99-115. (PMID: 30470818)
Adv Funct Mater. 2021 Feb 17;31(8):. (PMID: 37197212)
Nat Rev Clin Oncol. 2023 Jan;20(1):33-48. (PMID: 36307534)
Biomaterials. 2021 Feb;269:120621. (PMID: 33383301)
Nat Commun. 2019 May 20;10(1):2141. (PMID: 31105267)
Eur Urol. 2010 Jul;58(1):173-7. (PMID: 20334965)
ACS Appl Mater Interfaces. 2021 Mar 17;13(10):11683-11695. (PMID: 33656325)
Bioact Mater. 2021 Jul 14;9:15-28. (PMID: 34820552)
Nano Lett. 2022 Aug 10;22(15):6418-6427. (PMID: 35856800)
Nat Nanotechnol. 2021 Oct;16(10):1150-1160. (PMID: 34354264)
Trends Pharmacol Sci. 2018 Aug;39(8):766-781. (PMID: 30032745)
Int J Pharm. 2023 Jun 25;641:123082. (PMID: 37244464)
Biomaterials. 2020 Mar;233:119755. (PMID: 31927233)
Colloids Surf B Biointerfaces. 2020 Sep;193:111109. (PMID: 32416521)
Mater Today Bio. 2022 May 13;14:100288. (PMID: 35647513)
Nanoscale Horiz. 2021 Feb 1;6(2):120-131. (PMID: 33206735)
N Engl J Med. 1986 Dec 25;315(26):1650-9. (PMID: 3537791)
Oncotarget. 2016 Sep 27;7(39):64505-64511. (PMID: 27542274)
Theranostics. 2021 Jan 1;11(5):2218-2231. (PMID: 33500721)
Int J Mol Sci. 2020 May 09;21(9):. (PMID: 32397535)
Cancers (Basel). 2020 Oct 12;12(10):. (PMID: 33053779)
Int J Cancer. 2021 Apr 5;:. (PMID: 33818764)
ACS Appl Mater Interfaces. 2021 Feb 24;13(7):8026-8041. (PMID: 33577301)
Biomater Sci. 2020 Jan 21;8(2):552-568. (PMID: 31769765)
Oncotarget. 2018 May 25;9(40):25808-25825. (PMID: 29899823)
J Control Release. 2023 Sep;361:212-235. (PMID: 37517543)
Adv Healthc Mater. 2020 Jan;9(1):e1900996. (PMID: 31746153)
Front Immunol. 2021 Feb 25;12:622306. (PMID: 33717125)
Cancer Immunol Immunother. 2016 Oct;65(10):1243-8. (PMID: 27034234)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Apr 25;51(2):241-250. (PMID: 35462463)
Annu Rev Immunol. 2013;31:51-72. (PMID: 23157435)
Blood. 2018 Jan 4;131(1):49-57. (PMID: 29118009)
Dis Colon Rectum. 1991 Jul;34(7):600-4; discussion 604-5. (PMID: 1711439)
Nat Commun. 2019 Apr 12;10(1):1704. (PMID: 30979885)
Photodiagnosis Photodyn Ther. 2020 Sep;31:101876. (PMID: 32534246)
Nat Biomed Eng. 2021 Nov;5(11):1348-1359. (PMID: 34385695)
Immunol Rev. 2008 Apr;222:155-61. (PMID: 18364000)
Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605)
Front Immunol. 2015 May 26;6:263. (PMID: 26074923)
Clin Exp Dermatol. 1999 May;24(3):143-8. (PMID: 10354165)
Nanomedicine (Lond). 2020 Jan;15(1):77-92. (PMID: 31868112)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Nat Mater. 2020 Dec;19(12):1362-1371. (PMID: 32778816)
Int Immunopharmacol. 2015 Sep;28(1):44-51. (PMID: 26033489)
Int J Cancer. 2016 Sep 15;139(6):1372-8. (PMID: 27136745)
Nat Commun. 2022 Jun 27;13(1):3676. (PMID: 35760796)
J Colloid Interface Sci. 2022 Nov;625:145-157. (PMID: 35716610)
J Immunol. 2010 Nov 15;185(10):5953-61. (PMID: 20944000)
Mol Cancer. 2022 Sep 26;21(1):184. (PMID: 36163047)
Immunobiology. 2017 Jan;222(1):11-20. (PMID: 26264743)
Nat Rev Cancer. 2012 Dec;12(12):860-75. (PMID: 23151605)
Int J Pharm. 2022 Apr 5;617:121578. (PMID: 35176333)
Nanoscale. 2020 Apr 3;12(13):7051-7062. (PMID: 32186564)
Biomaterials. 2023 May;296:122089. (PMID: 36898223)
Chem Biol Interact. 2022 Feb 25;354:109830. (PMID: 35104486)
Int J Mol Sci. 2019 Feb 15;20(4):. (PMID: 30781344)
PLoS One. 2017 Mar 9;12(3):e0173241. (PMID: 28278159)
Trends Cancer. 2019 Nov;5(11):704-723. (PMID: 31735289)
J Oncol. 2022 Jun 25;2022:7211485. (PMID: 35794980)
J Urol. 2009 Oct;182(4):1371-7. (PMID: 19683262)
ACS Nano. 2019 Mar 26;13(3):2956-2968. (PMID: 30789699)
Adv Sci (Weinh). 2018 Feb 26;5(5):1700891. (PMID: 29876215)
Adv Sci (Weinh). 2019 Mar 13;6(10):1802157. (PMID: 31131193)
Asian J Pharm Sci. 2020 Mar;15(2):145-157. (PMID: 32373196)
Transplantation. 1978 Jan;25(1):23-6. (PMID: 145675)
Int J Mol Sci. 2021 May 27;22(11):. (PMID: 34071836)
Laryngoscope. 2020 Sep;130(9):E490-E498. (PMID: 31593308)
Nat Commun. 2022 Oct 10;13(1):5974. (PMID: 36216803)
ACS Nano. 2023 Jan 3;:. (PMID: 36595443)
Cancer Immunol Res. 2017 Jan;5(1):9-16. (PMID: 27941003)
Nat Commun. 2022 May 19;13(1):2794. (PMID: 35589680)
ACS Nano. 2018 Aug 28;12(8):8633-8645. (PMID: 30005164)
Int J Nanomedicine. 2017 Jan 16;12:515-531. (PMID: 28144136)
Nanoscale Res Lett. 2021 Jan 7;16(1):9. (PMID: 33411055)
Acta Biomater. 2022 Oct 15;152:473-483. (PMID: 36087872)
ESMO Open. 2020 Jul;4(Suppl 3):e000733. (PMID: 32611557)
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674. (PMID: 32699309)
Front Immunol. 2022 Jul 07;13:840029. (PMID: 35874739)
Lab Invest. 2019 Jun;99(6):777-792. (PMID: 30683902)
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41829-41841. (PMID: 31617343)
Biomater Sci. 2021 Nov 23;9(23):8019-8031. (PMID: 34718362)
Sci Adv. 2022 May 27;8(21):eabn3883. (PMID: 35622914)
J Am Chem Soc. 2022 Jan 19;144(2):787-797. (PMID: 34985903)
Adv Sci (Weinh). 2020 Jul 29;7(17):2000411. (PMID: 32995118)
Nature. 2017 Mar 16;543(7645):428-432. (PMID: 28273064)
ACS Appl Mater Interfaces. 2022 May 17;:. (PMID: 35578899)
J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):135-155. (PMID: 33398516)
Adv Healthc Mater. 2022 Aug;11(15):e2200524. (PMID: 35611682)
J Cancer. 2015 Jun 23;6(8):717-26. (PMID: 26185533)
World J Gastroenterol. 2018 Dec 28;24(48):5418-5432. (PMID: 30622371)
ACS Appl Mater Interfaces. 2019 Nov 20;11(46):43393-43408. (PMID: 31701733)
ACS Appl Mater Interfaces. 2022 Sep 21;14(37):41834-41850. (PMID: 36073504)
Biomaterials. 2021 Feb;269:120648. (PMID: 33445099)
ACS Appl Mater Interfaces. 2020 Jul 15;12(28):31292-31308. (PMID: 32551473)
J Exp Clin Cancer Res. 2021 Feb 18;40(1):74. (PMID: 33602280)
Adv Sci (Weinh). 2022 Nov;9(31):e2202332. (PMID: 36156451)
J Exp Med. 2005 Dec 19;202(12):1691-701. (PMID: 16365148)
Colloids Surf B Biointerfaces. 2023 Aug;228:113438. (PMID: 37421763)
ACS Appl Mater Interfaces. 2020 Jul 8;12(27):30031-30043. (PMID: 32459093)
Transl Oncol. 2020 Oct;13(10):100823. (PMID: 32652470)
ACS Omega. 2022 Sep 16;7(38):34685-34692. (PMID: 36188330)
Adv Mater. 2023 Nov;35(45):e2303722. (PMID: 37748441)
Front Pharmacol. 2018 Jan 26;9:27. (PMID: 29434548)
Small. 2021 Apr;17(14):e2007494. (PMID: 33711191)
Cell Res. 2020 Aug;30(8):660-669. (PMID: 32467592)
Biomater Sci. 2022 May 17;10(10):2577-2589. (PMID: 35393988)
J Hematother. 1993 Spring;2(1):43-62. (PMID: 7921966)
J Control Release. 2015 Dec 28;220(Pt B):600-7. (PMID: 26210440)
Nanoscale. 2021 Mar 12;13(9):4705-4727. (PMID: 33625411)
Drug Resist Updat. 2021 Dec;59:100787. (PMID: 34840068)
J Exp Med. 2002 Feb 4;195(3):335-41. (PMID: 11828008)
Front Immunol. 2022 May 04;13:884648. (PMID: 35603208)
Cell Mol Life Sci. 2021 Jul;78(13):5303-5324. (PMID: 34037806)
Theranostics. 2020 Jan 1;10(3):1281-1295. (PMID: 31938065)
BioDrugs. 2002;16(6):419-31. (PMID: 12463765)
Front Endocrinol (Lausanne). 2022 Aug 15;13:988295. (PMID: 36046791)
Nat Mater. 2020 May;19(5):566-575. (PMID: 31932672)
Acta Pharm Sin B. 2020 Aug;10(8):1382-1396. (PMID: 32963938)
Pharmacol Ther. 2022 Jul;235:108114. (PMID: 35122833)
Biomaterials. 2021 Mar;270:120678. (PMID: 33517205)
Biomaterials. 2020 May;240:119845. (PMID: 32085974)
Nano Res. 2022 Mar;15(3):2300-2314. (PMID: 36089987)
Adv Mater. 2021 Dec;33(48):e2103978. (PMID: 34580926)
J Cancer. 2021 Jan 1;12(1):54-64. (PMID: 33391402)
JAMA Oncol. 2019 Oct 01;5(10):1431-1438. (PMID: 31318392)
Pharmaceutics. 2022 Aug 04;14(8):. (PMID: 36015256)
Adv Mater. 2022 Mar;34(11):e2108908. (PMID: 34965614)
ACS Appl Mater Interfaces. 2023 Mar 9;:. (PMID: 36896475)
Acta Biomater. 2021 Oct 1;133:244-256. (PMID: 34000465)
Nanoscale. 2021 Jan 28;13(3):1745-1758. (PMID: 33432957)
J Nanobiotechnology. 2021 Dec 24;19(1):449. (PMID: 34952587)
Acta Biomater. 2017 Sep 1;59:269-282. (PMID: 28663143)
Asian J Pharm Sci. 2020 May;15(3):311-325. (PMID: 32636949)
Pharmacol Res. 2022 Oct;184:106454. (PMID: 36115525)
Biomaterials. 2022 Nov;290:121855. (PMID: 36257260)
Theranostics. 2020 Sep 23;10(25):11719-11736. (PMID: 33052243)
Genes Dis. 2019 Dec 20;8(1):25-37. (PMID: 33569511)
Int J Mol Sci. 2019 Dec 29;21(1):. (PMID: 31905745)
J Immunol. 2011 Feb 15;186(4):1891-7. (PMID: 21289313)
Nat Commun. 2019 Jul 26;10(1):3349. (PMID: 31350406)
Stem Cell Res Ther. 2021 Dec 4;12(1):592. (PMID: 34863287)
Cytokine Growth Factor Rev. 2018 Aug;42:37-46. (PMID: 30122459)
ACS Nano. 2018 Aug 28;12(8):8520-8530. (PMID: 30071159)
J Control Release. 2019 Feb 28;296:150-161. (PMID: 30682441)
Cancer J. 2010 Jul-Aug;16(4):354-9. (PMID: 20693847)
Angew Chem Int Ed Engl. 2023 Mar 6;62(11):e202214586. (PMID: 36597125)
Oncol Lett. 2021 Sep;22(3):664. (PMID: 34386086)
J Control Release. 2019 Jul 28;306:15-28. (PMID: 31132380)
ACS Nano. 2020 Dec 22;14(12):17442-17457. (PMID: 33166111)
CA Cancer J Clin. 2020 Mar;70(2):86-104. (PMID: 31944278)
J Am Chem Soc. 2016 Dec 28;138(51):16686-16695. (PMID: 27976881)
ACS Nano. 2020 May 26;14(5):5738-5753. (PMID: 32338871)
Cell Rep. 2022 Mar 8;38(10):110451. (PMID: 35263597)
Nanotheranostics. 2023 Jan 1;7(1):41-60. (PMID: 36593797)
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344)
Adv Mater. 2019 Jun;31(23):e1900192. (PMID: 30916367)

Y20210212 Wenzhou Municipal Science and Technology Bureau; LYY22H300001 Natural Science Foundation of Zhejiang Province; Health innovation talents program Health Commission of Zhejiang Province; YS2022-2-001 Zhejiang Medical Doctor Association

Keywords: Cancer; Immunogenic cell death; Immunotherapy; Nanomedicine; Phototherapy

0 (Nanoparticle Drug Delivery System)

Date Created: 20241017 Date Completed: 20241018 Latest Revision: 20241020

20250114

PMC11488210

10.1186/s12951-024-02925-3

39420366